Anti-Fbx32 antibody [EPR9148(2)]

• WB

Lab

Western blot - Anti-Fbx32 antibody [EPR9148(2)] (AB168372)

Blocking buffer : 5% NFDM/TBST

Dilution buffer : 5% NFDM/TBST

All lanes:

Western blot - Anti-Fbx32 antibody [EPR9148(2)] (ab168372) at 1/1000 dilution

Lane 1:

Mouse muscle at 20 µg

Lane 2:

Rat muscle at 20 µg

Predicted band size: 42 kDa

Observed band size: 42 kDa

false

• ICC/IF

Unknown

Immunocytochemistry/ Immunofluorescence - Anti-Fbx32 antibody [EPR9148(2)] (AB168372)

Immunofluorescent staining of A673 cells (fixed in 4% PFA) using purified ab168372 at a dilution of 1/200. An Alexa Fluor^® 555 goat anti-rabbit (ab150082) was used at a dilution of 1/500 and the cells were counter-stained with DAPI. The negative control is shown in the bottom right hand panel - for the negative control purified ab168372 was used at a dilution of 1/200 followed by an Alexa Fluor^® 488 goat anti-mouse antibody at a dilution of 1/400.

• ICC/IF

Unknown

Immunocytochemistry/ Immunofluorescence - Anti-Fbx32 antibody [EPR9148(2)] (AB168372)

Immunofluorescent analysis of A673 cells labeling Fbx32 with ab168372 at 1/250 dilution.

• WB

Unknown

Western blot - Anti-Fbx32 antibody [EPR9148(2)] (AB168372)

All lanes:

Western blot - Anti-Fbx32 antibody [EPR9148(2)] (ab168372) at 1/1000 dilution

Lane 1:

mouse heart lysate at 10 µg

Lane 2:

rat muscle lysate at 10 µg

Secondary

All lanes:

Goat anti-rabbit HRP at 1/2000 dilution

Predicted band size: 42 kDa

false

• WB

Lab

Western blot - Anti-Fbx32 antibody [EPR9148(2)] (AB168372)

Blocking buffer : 5% NFDM/TBST

Dilution buffer : 5% NFDM/TBST

All lanes:

Western blot - Anti-Fbx32 antibody [EPR9148(2)] (ab168372) at 1/1000 dilution

All lanes:

Human skeletal muscle at 10 µg

Secondary

All lanes:

HRP anti-rabbit IgG (specific to non-reduced IgG) at 1/1000 dilution

Predicted band size: 42 kDa

Observed band size: 42 kDa

false

• WB

CiteAb

Western blot - Anti-Fbx32 antibody [EPR9148(2)] (AB168372)

Fbx32 western blot using anti-Fbx32 antibody [EPR9148(2)] ab168372. Publication image and figure legend from Zeng, X., Chen, S., et al., 2017, Oncotarget, PubMed 29069832.

ab168372 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab168372 please see the product overview.

AG/UnAG attenuates ubiquitin E3 legases expression in co-cultured myotubes(A) Western blot of atrogin-1, MuRF1 and GAPDH in C2C12 myotubes. (B) Quantification of atrogin-1 was normalized to GAPDH. Significant differences were detected between CO and any NC groups (#p < 0.001), between CO and CO+AG/UnAG groups (*P = 0.001, p < 0.001; respectively), by one-way ANOVA followed by Tukey test. (C) Quantification of MuRF1 was normalized to GAPDH. Significant differences were detected between CO and any NC groups (#P = 0.002), between CO and CO+AG/UnAG groups (*P = 0.015, P = 0.037; respectively), by one-way ANOVA followed by Tukey test. (D) The levels of atrogin-1 mRNA in C2C12 myotubes. mRNA levels were normalized to GAPDH. Significant differences were detected between NC and CO groups (#P = 0.024), between CO and CO+AG/UnAG groups (*P = 0.034, P = 0.033; respectively), by one-way ANOVA followed by Dunnett's T3 test. (E) The levels of MuRF1 mRNA in C2C12 myotubes. mRNA levels were normalized to GAPDH. Significant differences were detected between NC and CO groups (#P = 0.006, P = 0.006; P = 0.007 respectively), between CO and CO+AG groups (*P = 0.016, P = 0.012), by one-way ANOVA followed by Tukey test. Data are represented as mean ± SD.

false